For Our Patients
Clinical Trials and Research
Are you interested in enrolling in a retina research clinical trial? Eligible new patients may have the opportunity to participate in studies focused on the diagnosis and treatment of conditions affecting the retina, macula, and vitreous. Clinical research studies are available at our Orlando, Jacksonville, and Wildwood locations under the expert care of our dedicated clinical research team.
Explore Clinical Research Opportunities
Last updated on Friday, August 14, 2026
New patients interested in participating in a clinical research study may select Enroll in This Study to contact our research team. Please include: Your full name, the reason you're interested in participating, preferred Florida Retina Institute location. Our team will respond within 48 – 72 hours.
Below, you’ll find a list of active retina research studies currently enrolling eligible patients, along with detailed information about each study and the conditions being investigated:
RESEARCH LOCATION: ORLANDO
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration
Protocol ID: MK-8748-003 (TORRONTES)
ClinicalTrials.gov ID: NCT07496567
Sponsor: EyeBiotech Limited
This Phase 2/3 randomized, double-masked, multicenter clinical trial evaluates the safety and efficacy of intravitreal tiespectus, also known as EYE201 or MK-8748, compared with aflibercept in participants with neovascular age-related macular degeneration. The study is designed to determine whether tiespectus can provide vision outcomes comparable to aflibercept while evaluating its safety and treatment schedule.
Study to Evaluate the Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy Associated With AMD (Age-Related Macular Degeneration)
Protocol ID: ONL1204-GA-002 (Galaxy)
ClinicalTrials.gov ID: NCT06659445
Sponsor: ONL Therapeutics
This Phase 2 randomized, double-masked, sham-controlled, multicenter clinical trial evaluates two dose levels of intravitreal ONL1204 in patients with geographic atrophy associated with age-related macular degeneration. Researchers are evaluating the treatment’s safety and efficacy and whether ONL1204 may slow the progression of geographic atrophy and help preserve retinal structure and visual function.
A Study Investigating Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adults With Geographic Atrophy
Protocol ID: R3918-AMD-2326 (SIENNA)
ClinicalTrials.gov ID: NCT06541704
Sponsor: Regeneron Pharmaceuticals
This Phase 3 randomized, double-masked, placebo-controlled, multicenter clinical trial evaluates subcutaneously administered pozelimab in combination with cemdisiran, as well as cemdisiran administered alone. Researchers are assessing the treatments’ efficacy, safety and tolerability and whether inhibiting components of the complement system may slow the progression of geographic atrophy secondary to age-related macular degeneration.
Study to Assess the Injection Burden and Long-Term Preservation of Vision With Surabgene Lomparvovec
Protocol ID: M24-528 (ACHIEVE)
ClinicalTrials.gov ID: NCT07007065
Sponsor: AbbVie/REGENXBIO
This Phase 3b randomized, controlled, partially masked, multicenter clinical trial evaluates surabgene lomparvovec, also known as ABBV-RGX-314, in adults with previously treated neovascular age-related macular degeneration. The study is designed to determine whether this investigational gene therapy can preserve vision and control disease activity while reducing the treatment burden associated with repeated anti-VEGF injections.
A Study of APL-3007 in Combination With Syfovre in Patients With Geographic Atrophy
Protocol ID: APL3007-GA-201 (GALLOP)
ClinicalTrials.gov ID: NCT07215390
Sponsor: Apellis Pharmaceuticals, Inc.
This Phase 2 randomized, placebo-controlled, multicenter, masked clinical trial evaluates multidose APL-3007 administered in combination with Syfovre® (pegcetacoplan). Researchers are evaluating the treatment’s efficacy, safety, tolerability and pharmacodynamic effects and whether adding APL-3007 to pegcetacoplan may further slow the progression of geographic atrophy.
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy Secondary to AMD
Protocol ID: OTX-TKI-2025-NPDR-302 (HELIOS-3)
ClinicalTrials.gov ID: NCT07215390
Sponsor: Ocular Therapeutix, Inc.
This Phase 3 randomized, masked, multicenter clinical trial evaluates OTX-TKI, an investigational sustained-release axitinib implant, in adults with non-proliferative diabetic retinopathy. Researchers are evaluating whether sustained delivery of axitinib can safely improve diabetic retinopathy severity and reduce the risk of disease progression.
NAAVIGATE Study for Non-Proliferative Diabetic Retinopathy
Protocol ID: M24-415 (NAAVIGATE)
Sponsor: REGENXBIO
This clinical trial evaluates an investigational gene therapy for patients with non-proliferative diabetic retinopathy. Researchers are assessing whether the treatment can safely improve diabetic retinopathy severity, reduce disease progression and lower the risk of future vision-threatening complications.
RESEARCH LOCATION: JACKSONVILLE
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Protocol ID: VX01-DR-201
ClinicalTrials.gov ID: NCT06770933
Sponsor: Vantage Biosciences Ltd.
This Phase 2 randomized, double-masked, placebo-controlled, multicenter clinical trial evaluates daily oral VX-01 in adults with moderate to severe non-proliferative diabetic retinopathy without center-involved diabetic macular edema. Researchers are assessing the treatment’s efficacy and safety and whether VX-01 can slow diabetic retinopathy progression and reduce the risk of vision-threatening complications.
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)
Protocol ID: NCT05769153
ClinicalTrials.gov ID: NCT05769153
Sponsor: Alcon Research
This Phase 1/2 clinical trial evaluates the safety, preliminary treatment effects and durability of AR-14034, a sustained-release implant containing axitinib. The study includes an initial dose-escalation stage followed by a randomized, double-masked stage comparing single or repeat administration of AR-14034 with aflibercept. Researchers are assessing whether the implant can safely control disease activity while reducing treatment burden.
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Protocol ID: R3918-AMD-2326 (SIENNA)
ClinicalTrials.gov ID: NCT06541704
Sponsor: Regeneron Pharmaceuticals
TThis Phase 3 randomized, double-masked, placebo-controlled, multicenter clinical trial evaluates the safety, efficacy, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone compared with placebo in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to determine whether these investigational treatments can safely slow the progression of geographic atrophy associated with AMD.
RESEARCH LOCATION: WILDWOOD
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Protocol ID: ADX-038-202
ClinicalTrials.gov ID: NCT06990269
Sponsor: ADARx Pharmaceuticals
This Phase 2 randomized, masked, placebo-controlled study evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneously administered ADX-038, an investigational siRNA therapy, in patients with geographic atrophy secondary to age-related macular degeneration. The study is designed to assess whether systemic inhibition of complement factor B may slow the progression of GA lesions compared
to placebo, with the goal of addressing an unmet need in GA treatment
through a less invasive dosing approach than intravitreal therapies.
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002
Protocol ID: MK8748-002 (MALBEC)
ClinicalTrials.gov ID: NCT07440225
Sponsor: EyeBiotech Ltd.
This pivotal Phase 2/3 randomized, double-masked, multicenter clinical trial evaluates two dose levels of intravitreal tiespectus, also known as EYE201 or MK-8748, compared with aflibercept in adults with neovascular age-related macular degeneration. Researchers are evaluating whether tiespectus can provide vision outcomes comparable to aflibercept while assessing its safety and durability.
Study availability and enrollment status may change. Participation is subject to study-specific eligibility requirements and evaluation by the Florida Retina Institute clinical research team. Investigational treatments have not necessarily been approved by the U.S. Food and Drug Administration for the conditions being studied.
Upcoming Studies
RESEARCH LOCATION: ORLANDO
NOVA-1: Study of AR-14034 in Neovascular Age-Related Macular Degeneration. To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors RTE888-E001 (NOVA-1)Condition: Neovascular age-related macular degeneration (nAMD)
Sponsor: Alcon Research
This Phase 1/2 study evaluates AR-14034, an investigational sustained-release implant, in adults with neovascular age-related macular degeneration. The study compares different doses of AR-14034 with aflibercept and assesses safety, preliminary treatment effects and how long the investigational treatment may remain effective.
4FRONT-2: Study of 4D-150 in Neovascular Age-Related Macular Degeneration.
Condition: Neovascular age-related macular degeneration (nAMD)
Sponsor: 4D Molecular Therapeutics
This Phase 3, randomized, double-masked clinical trial evaluates a single intravitreal administration of 4D-150 compared with aflibercept in adults with neovascular age-related macular degeneration. Researchers are evaluating vision outcomes, safety, durability and whether the investigational treatment may reduce the need for frequent anti-VEGF injections.
RESEARCH LOCATION: WILDWOOD
MALLOW: Study of BI 3812465 in Diabetic Macular EdemaCondition: Diabetic macular edema (DME)
Sponsor: Boehringer Ingelheim
This Phase 1/2, first-in-human clinical trial evaluates multiple dose levels of BI 3812465 administered by intravitreal injection in adults with diabetic macular edema. The study is primarily designed to assess safety and tolerability while also helping researchers select an appropriate dose for future clinical development.
SITALA: Study of STL-303 in Geographic Atrophy STL303-202 (SITALA)
Condition: Geographic atrophy secondary to age-related macular degeneration
Sponsor: Sitala Bio
This clinical trial evaluates the safety and efficacy of STL-303 in adults with geographic atrophy secondary to age-related macular degeneration. The investigational treatment is being studied to determine whether it can safely slow the progression of geographic atrophy compared with a control treatment.
HELIOS-3: Study of Axitinib Intravitreal Implant in Non-Proliferative Diabetic Retinopathy
Condition: Non-proliferative diabetic retinopathy (NPDR)
Sponsor: Ocular Therapeutics
This Phase 3, randomized, masked clinical trial evaluates one or two administrations of an investigational sustained-release axitinib intravitreal implant compared with a sham procedure in adults with moderately severe to severe non-proliferative diabetic retinopathy. Researchers are assessing safety and whether the implant can improve diabetic retinopathy severity and reduce the risk of disease progression.
Planned Study of BGE-102 in Diabetic Macular Edema BGE-102-004
Condition: Diabetic macular edema (DME)
Sponsor: BioAge Labs
This planned Phase 1b/2a proof-of-concept study will evaluate BGE-102, an investigational oral NLRP3 inhibitor, in adults with diabetic macular edema. The study is expected to assess safety, biological activity and preliminary evidence of treatment benefit.
Study of MK-8748 in Diabetic Macular Edema
Condition: Diabetic macular edema (DME)
Sponsor: Merck
This randomized, double-masked clinical trial evaluates MK-8748, also known as tiespectus, in adults with diabetic macular edema. Researchers will assess its safety and its effects on vision and retinal disease compared with an established anti-VEGF treatment.
Studies closed for Enrollment
For more information about clinical trials or if you should have any questions, please feel free to contact us.
